Pharmacists in Ferriday, LA Accepting Medicare

9 Pharmacists found. Showing 1 - 9

Mr. Frank Randolph Smith, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 114 Louisiana Ave, Ferriday, LA 71334 Phone: 318-757-3811    Fax: 318-757-4106

Mrs. Judy Vogt Green, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 114 Louisiana Ave, Ferriday, LA 71334 Phone: 318-757-3811    Fax: 318-757-4106

Angela Parish Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 109 Ee Wallace Blvd N, Ferriday, LA 71334 Phone: 318-757-4811    Fax: 318-757-4439

Ms. Lauren Hall Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 300 Desoto Rd, Ferriday, LA 71334 Phone: 318-757-1055

William Carroll Colvin, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 114 Serio Blvd, Ferriday, LA 71334 Phone: 318-757-4114    Fax: 318-757-4111

Mr. Christopher Lee Vaughan, P. D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 109 Ee Wallace Blvd N, Ferriday, LA 71334 Phone: 318-757-4811    Fax: 318-757-4439

Jessica Bradley Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2094 Ee Wallace Blvd N, Ferriday, LA 71334 Phone: 318-757-8172    Fax: 318-757-0762

Scott Emfinger Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 114 Serio Blvd, Ferriday, LA 71334 Phone: 318-757-3035

Charles Edward Maier, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 114 Serio Blvd, Ferriday, LA 71334 Phone: 318-757-4114    Fax: 318-757-4111

News Archive

Preliminary results from Phase 3 AVERROES trial in atrial fibrillation to be presented at cardiology congress 2010

Bristol-Myers Squibb Company and Pfizer report that preliminary results from the Phase 3 AVERROES clinical trial of the investigational drug apixaban compared with acetylsalicylic acid (ASA, or aspirin) in patients with atrial fibrillation expected to be or demonstrated to be unsuitable for warfarin therapy will be presented at the European Society of Cardiology Congress 2010. The results will be presented during the "Hot Line" session on August 31, 2010, in Stockholm, Sweden.

BioAlliance Pharma enters license deal with Sosei to commercialize Loramyc in Japan

BioAlliance Pharma, a company dedicated to specialty and orphan pharma products in oncology and supportive care, today announced that it has entered into an exclusive licensing agreement with Sosei Co. Ltd. for commercialization rights in Japan for Loramyc muco-adhesive buccal tablet.

Researchers use genomic technologies to better understand risk factor for stomach cancer

A research team led by National University Health System and Duke-NUS Medical School has used genomic technologies to better understand intestinal metaplasia, a known risk factor for gastric (stomach) cancer.

Tenet third quarter adjusted EBITDA decreases 15.4% to $203 million

Tenet Healthcare Corporation today reported adjusted EBITDA of $203 million for the quarter ended September 30, 2010, a decrease of $37 million, or 15.4 percent, compared to $240 million for the third quarter of 2009. Net income attributable to common shareholders for the third quarter of 2010 was $932 million, or $1.68 per diluted share, compared to a net loss of $3 million, or $0.01 per diluted share, for the third quarter of 2009.

Read more Medical News

› Verified 1 days ago